Becton, Dickinson and Company

NYSE BDX

Becton, Dickinson and Company Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -5.51 B

Becton, Dickinson and Company Net Cash Used For Investing Activities is USD -5.51 B for the Trailing 12 Months (TTM) ending September 30, 2024, a -670.11% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.
  • Becton, Dickinson and Company Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -716.00 M, a 77.84% change year over year.
  • Becton, Dickinson and Company Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -3.23 B, a -71.86% change year over year.
  • Becton, Dickinson and Company Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -1.88 B, a -52.60% change year over year.
  • Becton, Dickinson and Company Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -1.23 B, a -66.26% change year over year.
Key data
Date Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure
Market news
Loading...
SV Wall Street
NYSE: BDX

Becton, Dickinson and Company

CEO Mr. Thomas E. Polen Jr.
IPO Date Feb. 21, 1973
Location United States
Headquarters 1 Becton Drive
Employees 70,000
Sector Healthcare
Industries
Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Similar companies

HAE

Haemonetics Corporation

USD 69.05

-0.60%

RGEN

Repligen Corporation

USD 166.21

-0.79%

COO

The Cooper Companies, Inc.

USD 96.55

-1.58%

TFX

Teleflex Incorporated

USD 180.24

-1.42%

WST

West Pharmaceutical Services, Inc.

USD 341.55

-0.69%

RMD

ResMed Inc.

USD 236.18

-8.33%

XRAY

DENTSPLY SIRONA Inc.

USD 19.76

-2.71%

ICUI

ICU Medical, Inc.

USD 164.36

-0.93%

HOLX

Hologic, Inc.

USD 72.14

-0.04%

ANGO

AngioDynamics, Inc.

USD 11.41

-8.43%

StockViz Staff

February 3, 2025

Any question? Send us an email